Prostate Cancer Coverage from Every Angle


Phase III Trial of Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2024: Cognitive Function With Abiraterone vs Enzalutamide in Metastatic Prostate Cancer
ASCO GU 2024: Dose-Escalation vs Conventional Radiotherapy in High-Risk Prostate Cancer
ASCO GU 2024: Suspending Enzalutamide Monotherapy in High-Risk, Biochemically Recurrent Prostate Cancer
Society of Women in Urologic Oncology Elects Inaugural Chair
Does Adding Radium-223 to Third-Line Therapy Offer Survival Benefit in Metastatic Prostate Cancer?
SUO 2023: Toxicity Trends With Radioligand Therapy for Prostate Cancer
SUO 2023: Is Radioligand Therapy Safe for Patients With Prostate Cancer and Baseline Cytopenia?
Understanding Men’s Communication Preferences When Discussing Prostate Cancer Screening
FDA Approves Expanded Enzalutamide Indication for High-Risk Nonmetastatic Prostate Cancer
PARP Inhibitors and Prostate Cancer: Perceptions of Surveyed Practicing Oncologists
Alone or With Leuprolide, Enzalutamide May Help to Stop Spread of Prostate Cancer
ESMO 2023: Pembrolizumab Plus Enzalutamide Therapy Metastatic Prostate Cancer
ESMO 2023: New Insight on Treating High-Risk Prostate Cancer From 30 Years of Data
Can Radiotherapy Prime Immune System in Oligometastatic Prostate Cancer?
ESMO 2023: Does Adjuvant Radiotherapy Offer Benefit After Radical Prostatectomy?
ESMO 2023: Phase II Results With Enzalutamide Plus Radioligand Therapy in Prostate Cancer
ESMO 2023: Early Results With Novel Bispecific Antibody in Metastatic Prostate Cancer
Conventional Versus Stereotactic Proton Therapy for Early-Stage Prostate Cancer
ASTRO 2023: Disease Progression–Directed Therapy May Postpone Next-Line Treatment of Oligoprogressive Prostate Cancer
ESMO 2023: Is There a Role for Adjuvant Radiotherapy After Radical Prostatectomy?
ASTRO 2023: Impact of Testosterone Recovery With Salvage Radiotherapy and ADT
ASTRO 2023: Predicting Late Toxicity From External-Beam Radiotherapy for Prostate Cancer
ASTRO 2023: Is Less More in High-Dose–Rate Brachytherapy for Localized Prostate Cancer?
ASTRO 2023: Strategy for Reducing Genomic Testing Inequities in Prostate Cancer
ASTRO 2023: Enzalutamide Therapies After Radiotherapy for High-Risk Prostate Cancer
ASTRO 2023: Fewer, Higher Doses of SBRT for Localized Prostate Cancer
SNMMI Weighs in on Use of Radionuclide Therapy for Metastatic Prostate Cancer
Out-of-Pocket Costs for Prostate Cancer Drugs in Medicare Part D Plans
Precision Radiation Technique for Prostate Cancer May Reduce Short-Term Toxicity
Beyond Brachytherapy: Does Adding EBRT Benefit Those With Intermediate-Risk Prostate Cancer?
Researchers Link Metabolic Biomarkers With Increased Risk of Prostate Cancer in Black Men
Prostate Cancer Prognosis in Asian Versus White Men
Predicting Recurrence of Prostate Cancer With PSMA PET Imaging

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.